1
Home
Companies

Viridian Therapeutics

#4190

Rank

$2.55B

Marketcap

US United States

Country

Viridian Therapeutics
Leadership team

Dr. Jonathan Violin M.B.A., Ph.D. (Co-Founder, CEO, Pres & Director)

Mr. Kristian Humer M.B.A. (CFO, Chief Bus. Officer, Principal Financial Officer & Principal Accounting Officer)

Dr. Barrett Katz CMO, M.B.A., M.D., MBA (Chief Medical Officer)

Products/ Services
Biotechnology, Health Care, Therapeutics
Headquarters
Waltham, Massachusetts, United States
Established
2019
Company Registration
SEC CIK number: 0001590750
Revenue
500K - 2M
Traded as
VRDN
Social Media
URL
https://www.viridiantherapeutics.com
Overview
Location

Summary
History
Mission
Vision
Key Team
Recognition and Award
References
Summary
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was founded in 2006 and is headquartered in Waltham, Massachusetts.
History

Viridian Therapeutics was founded in 2016 with the mission to develop precision treatments for previously intractable diseases. Our team has brought together the right expertise and experience to find therapies that work more effectively and safely than existing treatments. After forming our initial platform, we built on the insights we gained to identify key opportunities and make meaningful innovation.

Mission
Viridian’s mission is to improve global health by developing precision treatments that are more effective and safer than existing alternatives.
Vision
Viridian Therapeutics seeks to be the world’s most respected leader in the development of precision therapies for complex and difficult-to-treat diseases.
Key Team

Dr. Eric N. Olson Ph.D. (Co-Founder & Chairman of Scientific Advisory Board)

Dr. Michael R. Bristow M.D., Ph.D. (Co-Founder & Member of the Scientific Advisory Board)

Dr. Marvin H. Caruthers Ph.D. (Co-Founder & Scientific Advisory Board Member)

Mr. Vahe Bedian Ph.D. (Co-Founder & Scientific Advisor)

Ms. Carrie Melvin M.B.A. (Chief Operating Officer)

Dr. Rob Henderson Ph.D. (Chief Scientific Officer)

Mr. Todd James IRC (Sr. VP of Corp. Affairs & Investor Relations)

Recognition and Awards
Viridian Therapeutics has been recognized for excellence, innovation and leadership by such organizations and magazines as Fast Company, The Wall Street Journal, National Institutes of Health, the National Science Foundation, and the American Heart Association.
References

https://in.investing.com/equities/signal-genetics

https://finance.yahoo.com/quote/VRDN/profile?p=VRDN

https://www.crunchbase.com/organization/viridian-therapeutics

https://sec.report/CIK/0001590750

https://companiesmarketcap.com/

https://www.viridiantherapeutics.com

Dive deeper into fresh insights across Business, Industry Leaders and Influencers, Organizations, Education, and Investors for a comprehensive view.

Viridian Therapeutics
Leadership team

Dr. Jonathan Violin M.B.A., Ph.D. (Co-Founder, CEO, Pres & Director)

Mr. Kristian Humer M.B.A. (CFO, Chief Bus. Officer, Principal Financial Officer & Principal Accounting Officer)

Dr. Barrett Katz CMO, M.B.A., M.D., MBA (Chief Medical Officer)

Products/ Services
Biotechnology, Health Care, Therapeutics
Headquarters
Waltham, Massachusetts, United States
Established
2019
Company Registration
SEC CIK number: 0001590750
Revenue
500K - 2M
Traded as
VRDN
Social Media
URL
https://www.viridiantherapeutics.com